CLDND2
gene geneOn this page
Also known as MGC33839
Summary
CLDND2 (claudin domain containing 2, HGNC:28511) is a protein-coding gene on chromosome 19q13.41, encoding Claudin domain-containing protein 2 (Q8NHS1).
Predicted to be located in membrane. Predicted to be active in plasma membrane.
Source: NCBI Gene 125875 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 33 total
- MANE Select transcript:
NM_152353
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:28511 |
| Approved symbol | CLDND2 |
| Name | claudin domain containing 2 |
| Location | 19q13.41 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | MGC33839 |
| Ensembl gene | ENSG00000160318 |
| Ensembl biotype | protein_coding |
| Entrez | 125875 |
Gene structure
Transcript identifiers
Ensembl transcripts: 3 — 3 protein_coding
ENST00000291715, ENST00000593841, ENST00000601435
RefSeq mRNA: 1 — MANE Select: NM_152353
NM_152353
CCDS: CCDS12829
Canonical transcript exons
ENST00000291715 — 4 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001051422 | 51367886 | 51368026 |
| ENSE00001051426 | 51367457 | 51367576 |
| ENSE00001125214 | 51367098 | 51367215 |
| ENSE00001187329 | 51368409 | 51369003 |
Expression profiles
Bgee: expression breadth ubiquitous, 161 present calls, max score 95.16.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.3381 / max 69.3453, expressed in 1375 samples.
FANTOM5 promoters (4 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 182391 | 2.9135 | 1160 |
| 182390 | 1.2312 | 676 |
| 208912 | 0.1741 | 75 |
| 182392 | 0.0193 | 3 |
Top tissues by expression
254 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 95.16 | silver quality |
| granulocyte | CL:0000094 | 94.80 | gold quality |
| left testis | UBERON:0004533 | 92.15 | gold quality |
| right testis | UBERON:0004534 | 91.31 | gold quality |
| sperm | CL:0000019 | 89.39 | silver quality |
| testis | UBERON:0000473 | 88.28 | gold quality |
| apex of heart | UBERON:0002098 | 82.16 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 79.83 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 77.40 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 77.13 | gold quality |
| hypothalamus | UBERON:0001898 | 77.12 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 76.99 | gold quality |
| right lobe of liver | UBERON:0001114 | 76.88 | gold quality |
| spleen | UBERON:0002106 | 76.81 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 76.70 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 76.46 | gold quality |
| lower esophagus | UBERON:0013473 | 76.41 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 76.28 | gold quality |
| blood | UBERON:0000178 | 76.24 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 76.24 | gold quality |
| amygdala | UBERON:0001876 | 75.78 | gold quality |
| right frontal lobe | UBERON:0002810 | 75.71 | gold quality |
| right adrenal gland | UBERON:0001233 | 75.51 | gold quality |
| left adrenal gland | UBERON:0001234 | 75.50 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 75.48 | gold quality |
| prefrontal cortex | UBERON:0000451 | 75.17 | gold quality |
| left ovary | UBERON:0002119 | 74.97 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 74.82 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 74.76 | gold quality |
| right coronary artery | UBERON:0001625 | 74.74 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 3.27 |
Regulation
Is transcription factor: no
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Cldnd2 | ENSMUSG00000038973 |
| rattus_norvegicus | Cldnd2 | ENSRNOG00000037333 |
Paralogs (10): LIM2 (ENSG00000105370), NKG7 (ENSG00000105374), PMP22 (ENSG00000109099), GSG1 (ENSG00000111305), EMP1 (ENSG00000134531), EMP3 (ENSG00000142227), GSG1L (ENSG00000169181), TMEM202 (ENSG00000187806), EMP2 (ENSG00000213853), GSG1L2 (ENSG00000214978)
Protein
Protein identifiers
Claudin domain-containing protein 2 — Q8NHS1 (reviewed: Q8NHS1)
All UniProt accessions (2): Q8NHS1, M0R1J6
UniProt curated annotations — full annotation on UniProt →
Subcellular location. Membrane.
Similarity. Belongs to the PMP-22/EMP/MP20 family.
RefSeq proteins (1): NP_689566* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR004031 | PMP22/EMP/MP20/Claudin | Family |
| IPR004032 | PMP22_EMP_MP20 | Family |
| IPR050579 | PMP-22/EMP/MP20-like | Family |
Pfam: PF00822
UniProt features (5 total): transmembrane region 4, chain 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q8NHS1-F1 | 88.58 | 0.58 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 30 (showing top):
GATA4_Q3, MIKKELSEN_ES_ICP_WITH_H3K4ME3, LU_EZH2_TARGETS_UP, FIGUEROA_AML_METHYLATION_CLUSTER_5_DN, SETD7_TARGET_GENES, SNRNP70_TARGET_GENES, ZNF513_TARGET_GENES, GSE10273_LOW_IL7_VS_HIGH_IL7_AND_IRF4_IN_IRF4_8_NULL_PRE_BCELL_DN, GSE7219_WT_VS_NIK_NFKB2_KO_DC_DN, MANNE_COVID19_NONICU_VS_HEALTHY_DONOR_PLATELETS_UP, MANNE_COVID19_COMBINED_COHORT_VS_HEALTHY_DONOR_PLATELETS_UP, TTCYRGAA_UNKNOWN, DESCARTES_FETAL_PLACENTA_LYMPHOID_CELLS, THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_28DY_DN, HE_LIM_SUN_FETAL_LUNG_C1_SMG_CELL
GO Biological Process (0):
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| binding | 1 |
| membrane | 1 |
| cell periphery | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
324 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CLDND2 | MISP3 | Q96FF7 | 592 |
| CLDND2 | BPIFA3 | Q9BQP9 | 466 |
| CLDND2 | UQCC6 | Q69YU5 | 437 |
| CLDND2 | ANKRD39 | Q53RE8 | 432 |
| CLDND2 | CCDC102A | Q96A19 | 431 |
| CLDND2 | SAXO4 | Q7Z5V6 | 430 |
| CLDND2 | BPIFA2 | Q96DR5 | 415 |
| CLDND2 | DHRS13 | Q6UX07 | 399 |
| CLDND2 | BPIFB4 | P59827 | 397 |
| CLDND2 | SCNM1 | Q9BWG6 | 396 |
| CLDND2 | RIPOR1 | Q6ZS17 | 374 |
| CLDND2 | TTC38 | Q5R3I4 | 370 |
| CLDND2 | NPEPL1 | Q8NDH3 | 358 |
| CLDND2 | ACTR8 | Q9H981 | 351 |
| CLDND2 | PANK4 | Q9NVE7 | 329 |
IntAct
79 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| CLDND2 | LHFPL5 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDND2 | ELOVL4 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDND2 | TMEM80 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDND2 | SAR1A | psi-mi:“MI:0915”(physical association) | 0.560 |
| ANKRD13C | CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 | |
| BLCAP | CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| AQP6 | CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDND2 | REEP4 | psi-mi:“MI:0915”(physical association) | 0.560 |
| FAM209A | CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CPLX4 | CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDND2 | TMEM14B | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMPPE | CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDND2 | MTIF3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| EBP | CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| GPR37L1 | CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDND2 | GPR152 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RELL2 | CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SLC10A6 | CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MUC1 | CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| FFAR2 | CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDND2 | FAM210B | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLDND2 | ERGIC3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| GOLT1A | CLDND2 | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (30): CLDND2 (Two-hybrid), CLDND2 (Two-hybrid), CLDND2 (Two-hybrid), CLDND2 (Two-hybrid), CLDND2 (Two-hybrid), CLDND2 (Two-hybrid), CLDND2 (Two-hybrid), CLDND2 (Two-hybrid), CLDND2 (Two-hybrid), CLDND2 (Two-hybrid), CLDND2 (Two-hybrid), CLDND2 (Two-hybrid), CLDND2 (Two-hybrid), CLDND2 (Two-hybrid), CLDND2 (Two-hybrid)
ESM2 similar proteins: A5A6N6, D3ZQJ0, F1QIK8, O09117, O35912, O88662, P19075, P47801, P54848, P54849, P54850, P54851, P54852, P56748, Q12999, Q16563, Q2NKU9, Q32KP1, Q3ZBY0, Q4KL25, Q58DR6, Q5PPI7, Q5R9S6, Q5RAI2, Q5RAP8, Q5RCY3, Q5U1V9, Q5XHG6, Q66HH2, Q66IV3, Q6DHB5, Q6GPN9, Q6P742, Q6Y1E2, Q6ZUX7, Q7ZUB3, Q7ZWW7, Q7ZZL8, Q8BGA2, Q8BI08
Diamond homologs: P20274, P54825, P55344, P56563, Q8NHS1, Q99PA5, Q9D9H2
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
33 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 27 |
| Likely benign | 2 |
| Benign | 1 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
588 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 19:51367880:TCTCA:T | donor_loss | 1.0000 |
| 19:51367881:CTCA:C | donor_loss | 1.0000 |
| 19:51367882:TCA:T | donor_loss | 1.0000 |
| 19:51367883:CACC:C | donor_loss | 1.0000 |
| 19:51367884:A:AC | donor_gain | 1.0000 |
| 19:51367884:A:AT | donor_loss | 1.0000 |
| 19:51367884:ACCG:A | donor_gain | 1.0000 |
| 19:51367885:C:CC | donor_gain | 1.0000 |
| 19:51367885:C:CG | donor_loss | 1.0000 |
| 19:51367885:CCG:C | donor_gain | 1.0000 |
| 19:51367885:CCGC:C | donor_gain | 1.0000 |
| 19:51367854:G:A | donor_gain | 0.9900 |
| 19:51367862:G:A | donor_gain | 0.9900 |
| 19:51367932:G:A | donor_gain | 0.9900 |
| 19:51367113:T:A | donor_gain | 0.9800 |
| 19:51367490:C:T | acceptor_gain | 0.9800 |
| 19:51368027:C:CC | acceptor_gain | 0.9800 |
| 19:51367490:C:CT | acceptor_gain | 0.9700 |
| 19:51367491:A:T | acceptor_gain | 0.9700 |
| 19:51367858:G:A | donor_gain | 0.9700 |
| 19:51368408:CT:C | donor_gain | 0.9600 |
| 19:51367458:C:CT | acceptor_gain | 0.9500 |
| 19:51367881:CT:C | donor_loss | 0.9500 |
| 19:51368022:CGTGG:C | acceptor_gain | 0.9500 |
| 19:51367504:C:CT | acceptor_gain | 0.9400 |
| 19:51367850:C:A | donor_gain | 0.9400 |
| 19:51367879:GTCT:G | donor_loss | 0.9400 |
| 19:51367458:C:T | acceptor_gain | 0.9300 |
| 19:51367884:ACCGC:A | donor_gain | 0.9300 |
| 19:51367885:CCGCC:C | donor_gain | 0.9300 |
AlphaMissense
1079 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 19:51367487:A:G | W134R | 0.973 |
| 19:51367487:A:T | W134R | 0.973 |
| 19:51367157:G:C | F163L | 0.955 |
| 19:51367157:G:T | F163L | 0.955 |
| 19:51367159:A:G | F163L | 0.955 |
| 19:51367505:A:G | W128R | 0.952 |
| 19:51367505:A:T | W128R | 0.952 |
| 19:51368485:C:A | W31C | 0.945 |
| 19:51368485:C:G | W31C | 0.945 |
| 19:51368487:A:G | W31R | 0.937 |
| 19:51368487:A:T | W31R | 0.937 |
| 19:51367457:C:G | G144R | 0.936 |
| 19:51367215:C:T | G144D | 0.921 |
| 19:51367501:G:A | S129F | 0.921 |
| 19:51367509:G:C | F126L | 0.921 |
| 19:51367509:G:T | F126L | 0.921 |
| 19:51367511:A:G | F126L | 0.921 |
| 19:51367886:C:G | G104R | 0.916 |
| 19:51367886:C:T | G104R | 0.916 |
| 19:51367499:A:C | Y130D | 0.913 |
| 19:51367205:A:C | F147L | 0.902 |
| 19:51367205:A:T | F147L | 0.902 |
| 19:51367207:A:G | F147L | 0.902 |
| 19:51367210:A:G | C146R | 0.896 |
| 19:51368495:G:A | T28I | 0.895 |
| 19:51367489:C:T | G133E | 0.892 |
| 19:51367480:G:T | A136D | 0.890 |
| 19:51367474:G:C | P138R | 0.889 |
| 19:51368452:C:A | W42C | 0.888 |
| 19:51368452:C:G | W42C | 0.888 |
dbSNP variants (sampled 300 via entrez): RS1002323217 (19:51366731 T>A,G), RS1002963012 (19:51368782 C>A,G,T), RS1004336890 (19:51369261 G>A), RS1004369396 (19:51369003 C>CG), RS1004475309 (19:51369144 G>A,C,T), RS1005861978 (19:51369975 G>A,C), RS1006990223 (19:51370921 G>A), RS1007943211 (19:51366890 C>T), RS1008767136 (19:51367695 C>A,G,T), RS1008931827 (19:51369830 C>T), RS1009321962 (19:51366931 C>T), RS1010010624 (19:51370965 C>T), RS1010332986 (19:51368113 C>A), RS1010821340 (19:51366551 G>A,C,T), RS1011056672 (19:51369648 G>T)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST009391_1417 | Metabolite levels | 5.000000e-07 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0010452 | adenosine diphosphate measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
18 total (human), top 18 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol S | affects cotreatment, increases expression | 2 |
| Valproic Acid | decreases expression, increases methylation | 2 |
| bisphenol F | affects cotreatment, increases expression | 1 |
| kojic acid | decreases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| abrine | decreases expression | 1 |
| Acetaminophen | decreases expression | 1 |
| Atrazine | increases expression | 1 |
| Benzo(a)pyrene | decreases methylation | 1 |
| Dexamethasone | affects cotreatment, increases expression | 1 |
| Indomethacin | affects cotreatment, increases expression | 1 |
| Silicon Dioxide | decreases expression | 1 |
| Smoke | decreases expression | 1 |
| Testosterone | increases expression | 1 |
| 1-Methyl-3-isobutylxanthine | affects cotreatment, increases expression | 1 |
| Asbestos, Serpentine | decreases methylation | 1 |
| Lactic Acid | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.